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Abstract: Gingival overgrowth is a serious side effect that accompanies the use of amlodipine. Several
conflicting theories have been proposed to explain the fibroblast’s function in gingival overgrowth.
To determine whether amlodipine alters the fibrotic response, we investigated its effects on treated
gingival fibroblast gene expression as compared with untreated cells. Materials and Methods:
Fibroblasts from ATCC® Cell Lines were incubated with amlodipine. The gene expression levels of
12 genes belonging to the “Extracellular Matrix and Adhesion Molecules” pathway was investigated
in treated fibroblasts cell culture, as compared with untreated cells, by real time PCR. Results: Most
of the significant genes were up-regulated. (CTNND2, COL4A1, ITGA2, ITGA7, MMP10, MMP11,
MMP12, MMP26) except for COL7A1, LAMB1, MMP8, and MMP16, which were down-regulated.
Conclusion: These results seem to demonstrate that amlodipine has an effect on the extracellular
matrix of gingival fibroblast. In the future, it would be interesting to understand the possible effect of
the drug on fibroblasts of patients with amlodipine-induced gingival hyperplasia.
Keywords: Gingival overgrowth; gene expression; drugs; amlodipine
1. Introduction
Gingival overgrowth may have multiple causes, however drugs assumption is the most
common [1,2]. In addiction, drug-induced gingival overgrowth may be associated with a patient’s
genetic predisposition [3,4].
The three main classes of drugs inducing gingival overgrowth are anticonvulsants,
immunosuppressive, and antihypertensive agents [3,5–7]. The first report regarding gingival
overgrowth by the administration of amlodipine was published in 1994 [8]. Subsequently, other authors
reported the onset of gingival overgrowth as a side effect in patients who received 10 mg per day
of amlodipine within two months [9]. Gingival overgrowth manifests as a side effect within one to
three months after amlodipine administration [7,10]. Amlodipine shows a pharmacological profile,
as follows: long-acting dihydropyridine; coronary and peripheral arterial vasodilatation; headaches,
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facial flushing, dizziness, and oedema. The main oral side effect that is induced by amlodipine is
gingival overgrowth [11,12].
Gingival overgrowth that is induced by amlodipine (GOIA) must be stimulated by a threshold
concentration of amlodipine [13]. However the severity of GOIA is supposed to be related to the
concentration of amlodipine in oral fluids [13]. The mean dose of amlodipine reported to cause GOIA
in most of the subjects is 5 mg/day. Therefore, it may be suggested that the dosage and duration of
amlodipine may have an impact on GOIA [13]. Usually, the gingival manifestations of GOIA appear
within the first three months of the drug administration [14]. A longer duration of therapy may
increase the exposure of cells to amlodipine, and this may modify the apoptosis of cells, resulting in
hyperplasia [14]. Genetic susceptibility is one the factors influencing the severity of GOIA; in fact
multidrug resistant (MDR1) gene polymorphisms is supposed to alter the inflammatory response to
the amlodipine [15].
Poor plaque control is another risk factor in developing of GOIA. In fact, GOIA hampered routine
oral hygiene measures. Additionally, GOIA can favour the accumulation of bacterial plaque, which in
turn determines gingival inflammation, causing gingival overgrowth [14]. Amlodipoine, in presence
of proinflammatory cytokines (for example TNF-α), may favour the inhibition of apoptosis of human
gingival fibroblasts, thus promoting hyperplasia [16].
1.1. Genetic Factors
Evidence suggests that genetic factors, along with patient susceptibility, may play an important
role in the pathogenesis of GOIA [15]. A genetic predisposition can influence a number of factors in the
drug interactions, cells, and plaque-induced inflammation. These include the functional heterogeneity
of gingival fibroblasts, the collagenolytic activity, the drug-receptor binding, the drug metabolism,
collagen synthesis, and many other factors.
Since most types of pharmacological agents that are implicated in GOIA can have negative
effects on the flow of calcium ions across cell membranes, it has been postulated that these agents
can interfere with the synthesis and function of the collagenase [17]. This mechanism of action has
been demonstrated for Cyclosporine. In fact, a recent study in vitro have shown that human gingival
fibroblasts that were treated with relevant doses of Cyclosporine show significantly reduced levels of
secretion of MMP-1 and MMP-3; these reduced levels can contribute to the accumulation of components
of the extracellular matrix [18]. An animal study that showed low mRNA levels of collagenase in
situ further supported these results, accompanied by a decrease in phagocytosis and degradation of
collagen [19]. The genetic predisposition to GOIA has been studied for cyclosporine, while, for what
we know, not yet for amlodipine.
1.2. Objective
To determine whether amlodipine can alter the matrix deposition, we investigated its effects on
treated gingival fibroblast gene expression as compared with untreated cells.
2. Results
The PrestoBlue™ cell viability test was conducted to determine the optimal concentration of
amlodipine to be used for cell treatment that did not significantly affect cell viability. Based on this test,
the concentration used for the treatment was 1000 ng/mL.
The gene expression profile of 12 genes belonging to the “Extracellular Matrix and Adhesion
Molecules” pathway was analysed using Real time PCR (Figure 1). Table 1 reported the list gene and
their fold change.
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Figure 1. Gene expression profile of fibroblast treated with Amlodipine 1000 ng/mL. 
Among the up-regulated genes, there was CTNND2, which code for the cell adhesion protein 
Catenin Delta 2. Other up-regulated gens were the transmembrane receptor ITGA2 and ITGA7 and 
the basement membrane constituent LAMB1. Most of the extracellular matrix proteases were up-
regulated (MMP10, MMP11, MMP12, MMP26), except for MMP8 and MMP16, which were down-
regulated. Other genes that were significantly deregulated genes following the treatment with 
Amlodipine were COL7A1, which was down-regulated and the COL4A1 that was up-regulated. In 
Figure 1 the significantly expression levels of the genes up- and down-regulated in fibroblast cells 
treated with amlodipine were represented. 
3. Discussion 
The prevalence of GOIA might be as high as 38%, and it is 3.3 times more common in men than 
in women [20,21]. The pathogenesis may be different for different drugs, even if the oral 
manifestations of gingival overgrowth are similar. GOIA starts as an enlargement of the interdental 
papilla of keratinized portions of the gingiva, and it is characterized by an increase in the connective 
tissue component. Bacteria accumulation appears to be an important uncomfortable effect of GOIA. 

















Figure 1. Gene expression profile of fibroblast treated with Amlodipine 1000 ng/mL.
Table 1. Significant gene expression levels after 24 h treatment with Amlodipine, as compared with
untreated cells.
Gene Fold Change SD (+/−) Gene Function
CTNND2 2.29 0.03 Cell Adhesion Molecule
COL4A1 2.57 0.13 Collagens & Extracellular Matrix Structural constituent
COL7A1 0.38 0.04 Collagens & Extracellular Matrix Structural constituent
ITGA2 2.75 0.08 Transmembrane Receptor
ITGA7 2.90 0.77 Transmembrane Receptor
LAMB1 0.41 0.05 Basement Membrane Constituent
MMP8 0.06 0.01 Extracellular Matrix Protease
MMP10 2.27 0.03 Extracellular Matrix Protease
MMP11 2.09 0.24 Extracellular Matrix Protease
MMP12 3.88 1.09 Extracellular Matrix Protease
MMP16 0.44 0.02 Ex racellular Matrix Protease
MMP26 11.78 2.31 Extracellular Matrix Protease
Bold fonts indicate significant variation of gene expression level: fold change ≥ 2 and p value
≤ 0.05 for up-regulated genes, and fold change ≤ 0.5 and p value ≤ 0.05 for the significantly
down-regulated genes.
Among the up-regulated genes, there was CTNND2, which code for the cell adhesion protein
Catenin Delta 2. Other up-regulated gens were the transmembrane receptor ITGA2 and ITGA7 and the
basement membrane constituent LAMB1. Most of the extracellular matrix proteases were up-regulated
(MMP10, MMP11, MMP12, MMP26), except for MMP8 and MMP16, which were down-regulated.
Other genes that were significantly deregulated genes following the treatment with Amlodipine
were COL7A1, which was down-regulated and the COL4A1 that was up-regulated. In Figure 1 the
significantly expression levels of the genes up- and down-regulated in fibroblast cells treated with
amlodipine were represented.
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3. Discussion
The prevalence of GOIA might be as high as 38%, and it is 3.3 times more common in men than in
women [20,21]. The pathogenesis may be different for different drugs, even if the oral manifestations of
gingival overgrowth are similar. GOIA starts as an enlargement of the interdental papilla of keratinized
portions of the gingiva, and it is characterized by an increase in the connective tissue component.
Bacteria accumulation appears to be an important uncomfortable effect of GOIA. GOIA may impair oral
hygiene and lead to increased oral infections. Oral infection itself is a cause of gingival overgrowth [22].
In addiction, oral infection can potentially impair systemic health and could possibly compromise the
general health of patients [22].
The mechanism of action of GOIA is still unknown, however it may be a consequence of the
interaction between gingival fibroblasts, cellular and biochemical mediators of inflammation, and drug
metabolites [22,23].
Gingival overgrowth is documented more frequently after intake of with phenytoin and rarely
with others antihypertensive [24]. Furthermore, poor oral hygiene is indicated as an important risk
factor for the expression of GOIA [25,26].
Cross-sectional studies have reported the relationship between bacterial plaque and GOIA. In fact,
as previously reported, GOIA can favour the accumulation of bacterial plaque, which in turn determines
gingival inflammation, causing gingival overgrowth [26]. The underlying mechanism of GOIA still
remains to be fully understood, however two main inflammatory and non-inflammatory pathways
have already been suggested [27–29]. One hypothesis may be that amlodipine may induce the alteration
of collagenase activity as a consequence of decreased uptake of folic acid, blockage of aldosterone
synthesis in adrenal cortex, and consequent feedback increase in the adrenocorticotropic hormone level
and the up-regulation of keratinocyte growth factor [30]. Besides, inflammation may be a consequence
of the toxic effect of amlodipine in periodontal pocket associated with C pathogens, leading to the
up-regulation of several cytokine factors, such as transforming growth factor-beta 1 (TGF-β1) [9].
Another pathogenic mechanism of GOIA is focusing on the effects of amlodipine on gingival fibroblast
metabolism and genetic predisposition. In fact, only a subgroup of patients that were treated with this
amlodipine will develop GOIA, so it has been hypothesized that these individuals show an abnormal
susceptibility to the drug. In fact, elevated levels of protein synthesis, most of which is collagen,
characterize the fibroblast of GOIA in these patients. Treatment of GOIA is generally targeted on
drug substitution and preventive protocols [12,31]. Surgical intervention is recommended when these
measures fail to cause the resolution of GOIA. These treatment modalities, although effective, do not
necessarily prevent the recurrence of the lesions [12]. Surgery for treatment of GOIA must be carefully
assessed and it is normally performed for cosmetic/aesthetic needs before any functional consequences
are present [1,32]. Most reports of GOIA have required surgical intervention [25].
To our knowledge, our study is the first one analysing the effect of amlodipine on genes that belong
to the “Extracellular Matrix and Adhesion Molecules” pathway. In this study, gingival fibroblasts were
treated for 24 h with 1000 ng/mL of amlodipine. The gene expression profile of 12 genes that belong to
the “Extracellular Matrix and Adhesion Molecules” pathway was analysed. Most of the significant
genes were up-regulated. (CTNND2, COL4A1, ITGA2, ITGA7, MMP10, MMP11, MMP12, MMP26),
except for COL7A1, LAMB1, MMP8, and MMP16, which were down-regulated. These proteins
preferentially induce extra cellular matrix deposition. This study demonstrated that, in human gingival
fibroblasts that were cultivated in vitro, amlodipine could promote the activities of genes belonging to
the “fibroblast matrix and receptors”.
It might be part of the underlying reason for the persistent overgrowth of gingiva that was
seen when bacterial plaque and local inflammation are present during amlodipine therapy. In fact,
GOIA does not allow patient to maintain a good oral hygiene, and this is the reason why GOIA
always determines the presence of bacterial plaque and inflammation, which in turn determines
gingival overgrowth.
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The data presented here suggest that amlodipine may contribute to an extracellular matrix
deposition of human gingival fibroblasts inducing gingival overgrowth.
4. Materials and Methods
4.1. Primary Human Fibroblast Cells Culture
We used cells from ATCC® Cell Lines. The cryopreserved cells at the second passage were
cultured in 75 cm2 culture flasks containing DMEM medium (Sigma Aldrich, Inc., St Louis, Mo,
USA) supplemented with 20% fetal calf serum, antibiotics (Penicillin 100U/ml and Streptomycin 100
micrograms/ml-Sigma Aldrich, Inc., St Louis, Mo, USA).
Cell cultures were replicated for subsequent experiments and maintained in a water saturated
atmosphere at 37 ◦C and 5% CO2.
4.2. Cell Viability Test
A stock solution of amlodipine 1 mg/mL was prepared. Further dilutions were made with the
culture medium to the desired concentrations just before use. The cell lines were seeded into 96-well
plates at a density of 104 cells per well containing 100 µL of cell culture medium and incubated for
24 h to allow cell adherence. Serial dilution of amlodipine (5000 ng/mL, 2000 ng/mL, 1000 ng/mL,
500 ng/mL, 100 ng/mL) was added (three wells for each concentration). The cell culture medium alone
was used negative control.
After 24 h of incubation, cell viability was measured while using PrestoBlue™ Reagent Protocol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Briefly, the PrestoBlue™
solution (10 µL) was added into each well containing 90 µL of treatment solution. The plates were
then placed back into the incubator for 1 h, after which absorbance was measured at wavelengths of
570 nm excitation and 620 nm emission by an automated microplate reader (Sunrise™, Tecan Trading
AG, Switzerland). Comparing the average absorbance in drug treated wells with average absorbance
in control wells exposed to vehicle alone determined the percentage of viable cells.
4.3. Cell Treatment
Gingival fibroblasts were seeded at a density of 1.0 × 105 cells/ml into 9 cm2 (3 mL) wells and then
subjected to serum starvation for 16 hours at 37 ◦C. Cells were treated with 1000 ng/mL amlodipine
solution for 24 h. This solution was obtained in DMEM that was supplemented with 2% FBS, antibiotics
and aminoacids. Cell medium alone was used as control negative. The cells were maintained in
a humidified atmosphere of 5% CO2 at 37 ◦C. After the end of the exposure time, the cells were
trypsinized and processed for RNA extraction.
4.4. RNA Isolation, Reverse Transcription and Quantitative Real-Time RT-PCR
Total RNA was isolated from cultured cells using GenElute mammalian total RNA purification
miniprep kit (Sigma-Aldrich, Inc., St Louis, Mo, USA), according to manufacturer’s instructions.
Pure RNA was quantified at NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham,
Massachusetts, USA).
cDNA synthesis was performed, starting from 500 ng of total RNA, using PrimeScript RT Master
Mix (Takara Bio Inc, Kusatsu, Japan). The reaction was incubated at 37 ◦C for 15 min. and inactivated
by heating at 70 ◦C for 10 s.
cDNA was amplified by Real Time Quantitative PCR using the ViiA™ 7 System (Applied
Biosystems, Foster City, CA, USA).
All of the PCR reactions were performed in a 20 µL volume. Each reaction contained 10 µL of 2x
qPCRBIO SYGreen Mix Lo-ROX (Pcrbiosystems, London, UK), 400 nM concentration of each primer,
and cDNA. Table 2 reported the sequences of the primer that was used in the reaction.
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Table 2. Primers sequences of SYBR® Green assay.














Custom primers belonging to the “Extracellular Matrix and Adhesion Molecules” pathway were
purchased from Sigma Aldrich. All of the experiments were performed, including non-template
controls to exclude reagents contamination. PCR was performed, including two analytical replicates.
The amplification profile was initiated by 10 min. incubation at 95 ◦C, followed by two-step
amplification of 15 s at 95 ◦C and 60 s at 60 ◦C for 40 cycles. As final step, a melt curve dissociation
analysis was performed.
4.5. Statistical Analysis
The gene expression levels were normalized to the expression of the reference gene (RPL13) and
they were expressed as fold changes relative to the expression of the untreated cells. Quantification
was done with the delta/delta Ct calculation method.
5. Conclusions
In this study, most of the significantly genes belonging to the “extracellular matrix proteases”
pathway were up-regulated. These results seem to indicate that amlodipine has an effect on the
modulation of fibrosis response in gingival fibroblasts, up-regulating extracellular matrix proteases,
and favouring the deposition of fibrotic tissue. More explanatory results could probably be obtained
by using gingival fibroblasts in which the use of amlodipine seems to aggravate the fibrotic response
and the gingival overgrowth.
GOIA is no longer a rare occurrence. From one side, plaque accumulation is an inevitable
consequence of GOIA, and from the other, it favours gingival inflammation and overgrowth.
The duration of therapy, dosage, and individual genetic susceptibility are considered important
risk factors for the development of GOIA. Amlodipine is a widely used drug for the treatment of
hypertension and angina, so it is very important that doctors inform patients about side effects, such as
GOIA, and about the importance of preventive protocols. Dentists should be able to identify the
changes in the oral cavity that are related to the general health of their patients. The patients must
be informed of the tendency of certain drugs to cause gingival overgrowth and the associated oral
changes and the importance of effective oral hygiene.
Combination therapy consisting of surgical and non-surgical periodontal therapy with drug
substitution is the most reliable method in the management of GOIA.
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